| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 37 | 2024 | 3041 | 3.220 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 10 | 2024 | 1120 | 2.460 |
Why?
|
| Neoplasm Metastasis | 27 | 2024 | 1109 | 2.440 |
Why?
|
| Lung Neoplasms | 14 | 2024 | 2362 | 2.160 |
Why?
|
| Immunotherapy | 13 | 2024 | 682 | 1.760 |
Why?
|
| Radiosurgery | 11 | 2024 | 288 | 1.590 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2021 | 618 | 1.310 |
Why?
|
| Mucin-1 | 9 | 2020 | 45 | 1.250 |
Why?
|
| Combined Modality Therapy | 17 | 2024 | 1719 | 1.110 |
Why?
|
| Radiotherapy | 4 | 2024 | 333 | 1.080 |
Why?
|
| Radioimmunotherapy | 4 | 2024 | 27 | 1.070 |
Why?
|
| Biomarkers, Tumor | 8 | 2024 | 1549 | 1.050 |
Why?
|
| Liver Neoplasms | 8 | 2024 | 758 | 1.030 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2024 | 111 | 0.980 |
Why?
|
| Aneuploidy | 1 | 2024 | 57 | 0.950 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2020 | 1265 | 0.950 |
Why?
|
| Neoplasms, Second Primary | 2 | 2022 | 260 | 0.870 |
Why?
|
| Cooperative Behavior | 1 | 2023 | 179 | 0.830 |
Why?
|
| Urinary Bladder | 1 | 2024 | 246 | 0.790 |
Why?
|
| Humans | 80 | 2024 | 89357 | 0.790 |
Why?
|
| Neoplasm Invasiveness | 2 | 2024 | 576 | 0.790 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2024 | 401 | 0.780 |
Why?
|
| B7-H1 Antigen | 3 | 2024 | 274 | 0.770 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 46 | 0.770 |
Why?
|
| Patient Care Team | 1 | 2023 | 284 | 0.760 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 112 | 0.750 |
Why?
|
| Colorectal Neoplasms | 6 | 2023 | 981 | 0.680 |
Why?
|
| Homologous Recombination | 2 | 2017 | 52 | 0.670 |
Why?
|
| Prostatic Neoplasms | 6 | 2024 | 1769 | 0.620 |
Why?
|
| Gene Amplification | 1 | 2018 | 134 | 0.600 |
Why?
|
| Janus Kinase 2 | 1 | 2018 | 60 | 0.600 |
Why?
|
| STAT1 Transcription Factor | 4 | 2009 | 53 | 0.590 |
Why?
|
| Pyrrolidines | 1 | 2018 | 59 | 0.590 |
Why?
|
| Anthracyclines | 1 | 2017 | 38 | 0.570 |
Why?
|
| Neoplasm, Residual | 2 | 2017 | 181 | 0.540 |
Why?
|
| Sulfonamides | 1 | 2018 | 318 | 0.510 |
Why?
|
| Breast Neoplasms | 7 | 2017 | 3011 | 0.490 |
Why?
|
| Cell Line, Tumor | 16 | 2024 | 2558 | 0.480 |
Why?
|
| MicroRNAs | 5 | 2023 | 551 | 0.470 |
Why?
|
| Myeloid-Derived Suppressor Cells | 2 | 2024 | 26 | 0.460 |
Why?
|
| Drug Therapy | 1 | 2014 | 70 | 0.450 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 605 | 0.450 |
Why?
|
| Tumor Microenvironment | 4 | 2024 | 463 | 0.450 |
Why?
|
| Prognosis | 10 | 2021 | 3783 | 0.440 |
Why?
|
| Radiation Tolerance | 3 | 2019 | 173 | 0.440 |
Why?
|
| DNA Repair | 2 | 2022 | 362 | 0.440 |
Why?
|
| Mutation | 3 | 2024 | 4143 | 0.440 |
Why?
|
| Aged | 15 | 2024 | 19165 | 0.430 |
Why?
|
| Interferon Type I | 3 | 2024 | 185 | 0.420 |
Why?
|
| Radiation, Ionizing | 5 | 2021 | 121 | 0.420 |
Why?
|
| Animals | 32 | 2024 | 27371 | 0.400 |
Why?
|
| Mice | 21 | 2024 | 11761 | 0.380 |
Why?
|
| Capecitabine | 2 | 2024 | 98 | 0.380 |
Why?
|
| Endothelium, Vascular | 1 | 2012 | 433 | 0.360 |
Why?
|
| Neovascularization, Pathologic | 1 | 2012 | 364 | 0.350 |
Why?
|
| Signal Transduction | 10 | 2023 | 3385 | 0.350 |
Why?
|
| Gene Expression Profiling | 8 | 2020 | 1431 | 0.340 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2020 | 969 | 0.340 |
Why?
|
| Middle Aged | 15 | 2024 | 25974 | 0.340 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2009 | 82 | 0.330 |
Why?
|
| Survival Rate | 6 | 2024 | 1901 | 0.330 |
Why?
|
| Melanoma, Experimental | 3 | 2024 | 111 | 0.330 |
Why?
|
| Chemoradiotherapy | 3 | 2021 | 309 | 0.330 |
Why?
|
| Male | 20 | 2024 | 42411 | 0.320 |
Why?
|
| Female | 22 | 2024 | 46202 | 0.320 |
Why?
|
| Lipid Metabolism | 1 | 2009 | 199 | 0.300 |
Why?
|
| Energy Metabolism | 1 | 2009 | 277 | 0.300 |
Why?
|
| RNA-Binding Proteins | 3 | 2024 | 269 | 0.300 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 2415 | 0.290 |
Why?
|
| Gene Regulatory Networks | 2 | 2009 | 308 | 0.290 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2024 | 2566 | 0.280 |
Why?
|
| Chromosomes, Human, Pair 14 | 2 | 2018 | 49 | 0.280 |
Why?
|
| Inflammation | 1 | 2012 | 972 | 0.280 |
Why?
|
| Aged, 80 and over | 7 | 2024 | 6811 | 0.280 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2018 | 860 | 0.270 |
Why?
|
| Antibodies, Monoclonal | 2 | 2024 | 1412 | 0.270 |
Why?
|
| Neoplasms, Experimental | 3 | 2019 | 269 | 0.270 |
Why?
|
| Neoplasm Staging | 5 | 2024 | 2018 | 0.260 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 470 | 0.260 |
Why?
|
| Androgen Antagonists | 2 | 2024 | 154 | 0.260 |
Why?
|
| Mice, Nude | 5 | 2020 | 815 | 0.250 |
Why?
|
| Genomic Instability | 2 | 2017 | 80 | 0.250 |
Why?
|
| Brain Mapping | 1 | 2008 | 564 | 0.250 |
Why?
|
| DNA Replication | 2 | 2017 | 170 | 0.250 |
Why?
|
| Emotions | 1 | 2008 | 349 | 0.240 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2024 | 12 | 0.230 |
Why?
|
| Telomerase | 1 | 2024 | 62 | 0.230 |
Why?
|
| Quality of Life | 2 | 2024 | 1668 | 0.230 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 1723 | 0.230 |
Why?
|
| Cognition | 1 | 2008 | 580 | 0.220 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2024 | 108 | 0.220 |
Why?
|
| Adult | 9 | 2024 | 26607 | 0.220 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2024 | 66 | 0.220 |
Why?
|
| Cystectomy | 1 | 2024 | 110 | 0.210 |
Why?
|
| DNA Methylation | 2 | 2018 | 657 | 0.210 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2012 | 699 | 0.210 |
Why?
|
| Radiation Pneumonitis | 1 | 2022 | 21 | 0.210 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1365 | 0.200 |
Why?
|
| Follow-Up Studies | 4 | 2024 | 3666 | 0.200 |
Why?
|
| Epigenesis, Genetic | 2 | 2023 | 507 | 0.200 |
Why?
|
| NF-kappa B | 2 | 2023 | 466 | 0.200 |
Why?
|
| Transforming Growth Factor beta | 1 | 2023 | 324 | 0.190 |
Why?
|
| Cisplatin | 1 | 2024 | 618 | 0.190 |
Why?
|
| Light | 1 | 2022 | 292 | 0.190 |
Why?
|
| Apoptosis | 5 | 2018 | 1717 | 0.190 |
Why?
|
| Cell Proliferation | 4 | 2018 | 1652 | 0.190 |
Why?
|
| Retrospective Studies | 4 | 2023 | 9057 | 0.190 |
Why?
|
| Dendritic Cells | 1 | 2024 | 449 | 0.190 |
Why?
|
| Erythroid Precursor Cells | 1 | 2021 | 33 | 0.190 |
Why?
|
| Membrane Proteins | 2 | 2024 | 1224 | 0.190 |
Why?
|
| Chemokine CXCL10 | 2 | 2024 | 23 | 0.190 |
Why?
|
| Treatment Outcome | 8 | 2024 | 8241 | 0.180 |
Why?
|
| Butyrates | 1 | 2021 | 46 | 0.180 |
Why?
|
| Pneumonia | 1 | 2022 | 182 | 0.180 |
Why?
|
| Tumor Cells, Cultured | 3 | 2018 | 1057 | 0.180 |
Why?
|
| Disease Progression | 3 | 2020 | 1489 | 0.180 |
Why?
|
| Adenocarcinoma | 3 | 2016 | 1194 | 0.180 |
Why?
|
| Cell Survival | 4 | 2019 | 983 | 0.180 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2020 | 76 | 0.180 |
Why?
|
| Neuroendocrine Tumors | 1 | 2022 | 118 | 0.170 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2020 | 33 | 0.170 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 2 | 2018 | 60 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2020 | 126 | 0.170 |
Why?
|
| DEAD Box Protein 58 | 2 | 2016 | 11 | 0.170 |
Why?
|
| Colonic Neoplasms | 2 | 2015 | 573 | 0.160 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2012 | 695 | 0.160 |
Why?
|
| Class II Phosphatidylinositol 3-Kinases | 1 | 2018 | 9 | 0.160 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 131 | 0.160 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2022 | 665 | 0.150 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2022 | 394 | 0.150 |
Why?
|
| Brain | 1 | 2008 | 2285 | 0.150 |
Why?
|
| Urologic Neoplasms | 1 | 2018 | 84 | 0.150 |
Why?
|
| Interferon-beta | 2 | 2016 | 126 | 0.150 |
Why?
|
| Receptor, Notch1 | 1 | 2018 | 94 | 0.150 |
Why?
|
| Neuronal Plasticity | 1 | 2020 | 194 | 0.150 |
Why?
|
| Palliative Care | 1 | 2019 | 264 | 0.140 |
Why?
|
| T-Lymphocytes | 2 | 2021 | 1224 | 0.140 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2018 | 244 | 0.140 |
Why?
|
| DNA Damage | 2 | 2017 | 371 | 0.140 |
Why?
|
| Preoperative Period | 1 | 2017 | 94 | 0.140 |
Why?
|
| Adaptive Immunity | 3 | 2024 | 167 | 0.140 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2017 | 66 | 0.140 |
Why?
|
| Disease Models, Animal | 3 | 2024 | 2366 | 0.140 |
Why?
|
| Mice, Inbred C57BL | 7 | 2021 | 3218 | 0.140 |
Why?
|
| Pancreatic Neoplasms | 1 | 2022 | 669 | 0.130 |
Why?
|
| Prospective Studies | 5 | 2024 | 4289 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 424 | 0.130 |
Why?
|
| Biomarkers | 1 | 2022 | 1767 | 0.130 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2015 | 42 | 0.120 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 164 | 0.120 |
Why?
|
| Gene Knockdown Techniques | 2 | 2018 | 247 | 0.120 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 509 | 0.120 |
Why?
|
| RNA Helicases | 1 | 2014 | 35 | 0.110 |
Why?
|
| Prostate | 2 | 2020 | 393 | 0.110 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2014 | 64 | 0.110 |
Why?
|
| Mice, Knockout | 4 | 2024 | 2001 | 0.110 |
Why?
|
| Hospitalization | 1 | 2018 | 877 | 0.110 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2012 | 69 | 0.100 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2012 | 26 | 0.100 |
Why?
|
| Stress, Physiological | 1 | 2014 | 232 | 0.100 |
Why?
|
| Heterografts | 3 | 2018 | 102 | 0.100 |
Why?
|
| Ipilimumab | 2 | 2022 | 61 | 0.100 |
Why?
|
| Endothelial Cells | 2 | 2012 | 460 | 0.100 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2024 | 157 | 0.100 |
Why?
|
| Estrogen Receptor alpha | 2 | 2012 | 148 | 0.100 |
Why?
|
| Transcriptional Activation | 2 | 2012 | 294 | 0.100 |
Why?
|
| Myeloid Cells | 2 | 2023 | 100 | 0.100 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 479 | 0.090 |
Why?
|
| Interferon-gamma | 4 | 2019 | 451 | 0.090 |
Why?
|
| Receptors, Estrogen | 1 | 2012 | 393 | 0.090 |
Why?
|
| Glioma | 1 | 2012 | 294 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 988 | 0.090 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2023 | 97 | 0.090 |
Why?
|
| Tumor Burden | 2 | 2024 | 308 | 0.080 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2009 | 104 | 0.080 |
Why?
|
| X-Ray Therapy | 1 | 2008 | 6 | 0.080 |
Why?
|
| Immunity, Innate | 2 | 2024 | 430 | 0.080 |
Why?
|
| Interleukins | 1 | 2009 | 129 | 0.080 |
Why?
|
| Proteome | 1 | 2009 | 132 | 0.080 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2008 | 97 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2012 | 3448 | 0.080 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 2 | 2018 | 20 | 0.080 |
Why?
|
| HCT116 Cells | 2 | 2018 | 155 | 0.070 |
Why?
|
| MCF-7 Cells | 2 | 2018 | 114 | 0.070 |
Why?
|
| Neoplasm Transplantation | 3 | 2016 | 397 | 0.070 |
Why?
|
| Cells, Cultured | 1 | 2012 | 2884 | 0.070 |
Why?
|
| Cholesterol | 1 | 2009 | 359 | 0.070 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2020 | 198 | 0.070 |
Why?
|
| Genetic Therapy | 1 | 2008 | 370 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2010 | 595 | 0.070 |
Why?
|
| Recurrence | 1 | 2009 | 1144 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 2009 | 540 | 0.060 |
Why?
|
| Mice, SCID | 2 | 2016 | 261 | 0.060 |
Why?
|
| Leuprolide | 1 | 2024 | 35 | 0.060 |
Why?
|
| Etoposide | 1 | 2024 | 206 | 0.060 |
Why?
|
| CTLA-4 Antigen | 1 | 2024 | 139 | 0.060 |
Why?
|
| Cell Movement | 2 | 2019 | 784 | 0.060 |
Why?
|
| Mice, Transgenic | 2 | 2019 | 1574 | 0.060 |
Why?
|
| Carboplatin | 1 | 2024 | 312 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 851 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2024 | 156 | 0.050 |
Why?
|
| Methylation | 1 | 2023 | 268 | 0.050 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2024 | 171 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2022 | 51 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2023 | 561 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2022 | 77 | 0.050 |
Why?
|
| Metastasectomy | 1 | 2020 | 9 | 0.050 |
Why?
|
| Vancomycin | 1 | 2021 | 73 | 0.050 |
Why?
|
| Synaptophysin | 1 | 2020 | 11 | 0.040 |
Why?
|
| POU Domain Factors | 1 | 2020 | 8 | 0.040 |
Why?
|
| Aurora Kinase A | 1 | 2020 | 11 | 0.040 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2020 | 16 | 0.040 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2020 | 21 | 0.040 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2020 | 38 | 0.040 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2020 | 37 | 0.040 |
Why?
|
| RNA | 1 | 2023 | 580 | 0.040 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2020 | 100 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2021 | 682 | 0.040 |
Why?
|
| Rats | 3 | 2010 | 4041 | 0.040 |
Why?
|
| Gastrointestinal Tract | 1 | 2021 | 191 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2009 | 90 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2021 | 780 | 0.040 |
Why?
|
| Cell Line | 2 | 2016 | 2496 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 175 | 0.040 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2020 | 172 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 286 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2019 | 172 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2020 | 162 | 0.040 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2020 | 121 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 58 | 0.040 |
Why?
|
| Azacitidine | 1 | 2018 | 147 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2021 | 511 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2018 | 188 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2020 | 211 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2012 | 956 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 281 | 0.040 |
Why?
|
| RNA, Long Noncoding | 1 | 2018 | 117 | 0.040 |
Why?
|
| Comorbidity | 1 | 2021 | 949 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2020 | 414 | 0.040 |
Why?
|
| Bacteria | 1 | 2021 | 478 | 0.040 |
Why?
|
| cdc25 Phosphatases | 1 | 2016 | 19 | 0.040 |
Why?
|
| Radiotherapy Dosage | 1 | 2018 | 470 | 0.030 |
Why?
|
| Remission Induction | 1 | 2018 | 740 | 0.030 |
Why?
|
| Transcription Factor RelA | 1 | 2016 | 49 | 0.030 |
Why?
|
| RNA, Small Untranslated | 1 | 2016 | 15 | 0.030 |
Why?
|
| Transcriptome | 1 | 2021 | 630 | 0.030 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2016 | 14 | 0.030 |
Why?
|
| Patient Safety | 1 | 2018 | 218 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2020 | 383 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2020 | 556 | 0.030 |
Why?
|
| Phenotype | 2 | 2015 | 2440 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2023 | 1653 | 0.030 |
Why?
|
| Receptors, CXCR3 | 1 | 2015 | 12 | 0.030 |
Why?
|
| Wnt Proteins | 1 | 2016 | 130 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2019 | 1534 | 0.030 |
Why?
|
| Luminescent Measurements | 1 | 2015 | 62 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 1150 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 838 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2015 | 138 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 691 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2015 | 136 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2015 | 195 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2023 | 1976 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2015 | 273 | 0.030 |
Why?
|
| Transcription, Genetic | 2 | 2009 | 1157 | 0.030 |
Why?
|
| beta Catenin | 1 | 2016 | 266 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 1184 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 557 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2016 | 640 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 922 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 598 | 0.030 |
Why?
|
| Peptides | 1 | 2016 | 648 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2012 | 31 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2020 | 2303 | 0.030 |
Why?
|
| Estradiol | 1 | 2012 | 251 | 0.020 |
Why?
|
| Glioblastoma | 1 | 2014 | 265 | 0.020 |
Why?
|
| Time Factors | 1 | 2020 | 5338 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2012 | 236 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2012 | 374 | 0.020 |
Why?
|
| Gene Expression | 1 | 2015 | 1310 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2016 | 1525 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2012 | 360 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 2661 | 0.020 |
Why?
|
| Mammary Glands, Human | 1 | 2009 | 24 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2010 | 231 | 0.020 |
Why?
|
| Cytotoxins | 1 | 2009 | 16 | 0.020 |
Why?
|
| Infant | 1 | 2016 | 3160 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2009 | 86 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2008 | 20 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2016 | 3731 | 0.020 |
Why?
|
| Etanercept | 1 | 2008 | 33 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2009 | 284 | 0.020 |
Why?
|
| Caspases | 1 | 2009 | 155 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2009 | 174 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2008 | 43 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2010 | 349 | 0.020 |
Why?
|
| Prostatectomy | 1 | 2012 | 477 | 0.020 |
Why?
|
| Protein Binding | 1 | 2012 | 1488 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2010 | 446 | 0.020 |
Why?
|
| Patient Selection | 1 | 2012 | 684 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2009 | 301 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 887 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 782 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2009 | 261 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2009 | 370 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2009 | 740 | 0.020 |
Why?
|
| Transfection | 1 | 2009 | 911 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2010 | 751 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2008 | 465 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2009 | 447 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2009 | 1214 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2009 | 755 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2009 | 2062 | 0.020 |
Why?
|
| Cytokines | 1 | 2009 | 803 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2009 | 3027 | 0.020 |
Why?
|
| Child | 1 | 2016 | 7174 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 975 | 0.010 |
Why?
|
| Lung | 1 | 2009 | 1263 | 0.010 |
Why?
|